Your trusted source for investing success

Tag: DNA

Tech Forecast and Promising Tech Stocks To Buy in 2017

Learn about breakthrough technology about to impact lives around the globe. We cover the entire industry in our FREE investor’s report.   Gain Access
Alliance Growers, BRIM Start ACMPR Application

Alliance Growers, BRIM Start ACMPR Application

Alliance Growers Corp. (CSE:ACG; FWB: 1LA; WKN: A2DFYX) (“Alliance Growers” or the “Company”) is pleased to report that the Company has commenced the ACMPR application with its partner Botanical Research In Motion International Inc. (“BRIM”).  Alliance and BRIM will begin construction of the Cannabis Botany Centre within the next 6

What Is Genomics?

What Is Genomics?

Genomics, the study of genetic information within all living beings provides an insight into a patient’s genetics which opens the possibility to provide a more personalized medicine system.

SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

SeeThruEquity Issues Update on DelMar Pharmaceuticals, Inc. (Nasdaq: DMPI)

SeeThruEquity, a leading New York City based independent equity research and corporate access firm focused on smallcap and microcap public companies, today announced that it has issued an update note on DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI).

The note is available here: DMPI October 2017 Update.

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI)) is a clinical-stage biotechnology firm

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals Presents Poster at AACR’s Ovarian Cancer Special Conference on the Mechanistic Rationale for VAL-083 Overcoming Treatment Resistance in Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced the presentation of a poster at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held October 1-4, 2017 in Pittsburgh, PA.  The poster entitled “Distinct mechanism of

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals Announces Fiscal Year 2017 Financial Results

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, announced its financial results for the year ended June 30, 2017.   DelMar executive management will host a business update conference call and live webcast for investors, analysts and other interested parties on Wednesday, October 4, 2017 at 4:30

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

DelMar Pharmaceuticals to Present at AACR Special Conference on Ovarian Cancer

 DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that it will be presenting an abstract at the American Association for Cancer Research (AACR) Special Conference: Addressing Critical Questions in Ovarian Cancer Research and Treatment, being held on October 1-4, 2017 in Pittsburgh, PA at the Wyndham Grand.

DelMar

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals Announces Issuance of New Patent on First-in-Class DNA-targeting Agent, VAL-083

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Patent and Trademark Office (USPTO) has issued to DelMar, United States Patent No. 9,759,698 covering improved analytical methods for analyzing and determining impurities in dianhydrogalactitol (VAL-083).

DelMar’s new patent strengthens the Company’s control over

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals Receives IND Allowance from FDA to Initiate Clinical Trials of VAL-083 for the Treatment of Ovarian Cancer

DelMar Pharmaceuticals, Inc. (NASDAQ: DMPI), a biopharmaceutical company focused on the development of new cancer therapies, today announced that the U.S. Food and Drug Administration (“FDA”) has allowed an additional Investigational New Drug Application (“IND”) to study its lead drug candidate VAL-083 as a potential treatment for ovarian cancer.

 “The opening of this

FREE Report - How Will Trump Affect Your Gold Investments? 

Trump’s policies are affecting gold. You should know what’s going on. Click here to get our FREE report.

Click here to get your free report!

Discover what the experts see coming in the Age of Trump with our INN Insider's Report free of charge! Includes expert insights into Trump and his effect on mining and gold.

 
Enter Your Log In Credentials
This setting should only be used on your home or work computer.

×

Privacy & Legal Policy

Privacy Policy

×
Investing News Network

Send this to a friend

Hi,
I thought you might find this interesting:
How to Invest in the Anti-Counterfeiting Market

URL: https://investingnews.com/daily/tech-investing/cybersecurity-investing/invest-anti-counterfeiting/